Quantcast
Home > Quotes > CHRS
CHRS

Coherus BioSciences, Inc. Common Stock (CHRS) Quote & Summary Data

$18.65
*  
0.20
1.08%
Get CHRS Alerts
*Delayed - data as of Jul. 20, 2018  -  Find a broker to begin trading CHRS now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 18.70 / $ 18.15
Share Volume
605,528
50 Day Avg. Daily Volume
813,722
Previous Close
$ 18.45
52 Week High / Low
$ 18.70 / $ 8.05
Market Cap
1,259,875,311
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
605,528
50 Day Avg. Daily Volume:
813,722

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -3.75

Trading Range

The current last sale of $18.65 is 131.68% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 18.70 $ 18.70
 Low: $ 18.15 $ 8.05

ETFs with CHRS as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
0.23% Inspire Small/Mid Cap Impact ETF (ISMD) +3.18 (12.13%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are a late-stage clinical biologics platform company focused on the global biosimilar market. Biosimilars are an emerging class of protein-based therapeutics with high similarity to approved originator products on the basis of various physicochemical and structural properties, as well as safety, purity and potency. Our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our business is organized around therapeutic franchises: 1) Oncology biosimilar candidate, CHS-1701 for pegfilgrastim (Neulasta®), which has been filed for approval in Europe, and for which we expect to refile a BLA for potential approval in the United States ("U.S.  ... More ...  

Risk Grade

Where does CHRS fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 18.45
Open Date:
Jul. 20, 2018
Close Price:
$ 18.45
Close Date:
Jul. 20, 2018

Consensus Recommendation

Analyst Info